Literature DB >> 1805323

The unseen sample in cohort studies: estimation of its size and effect. Multicenter AIDS Cohort Study.

D R Hoover1, A Muñoz, V Carey, N Odaka, J M Taylor, J S Chmiel, J Armstrong, S H Vermund.   

Abstract

Recruitment of disease-free subjects into cohort studies and measurement of their time from exposure/infection to disease selectively excludes individuals (the unseen sample) who had earlier exposure and who have shorter times to disease. The unseen and observed samples may differ in other characteristics in addition to incubation period and exposure/infection time. For data with known truncation times, we develop non-parametric maximum likelihood estimates of the size, exposure/infection dates and distribution of incubation time in the unseen sample. We provide procedures to estimate and compensate for the biasing effects due to exclusion of the unseen sample in descriptive and survival analysis. We give consistency properties of these estimates and assess variability using bootstrap methods. One can use imputation to derive the above estimates from data with unknown truncation times that have been estimated parametrically. Application is made to an AIDS cohort study of over 5000 homosexual men. Important estimates obtained from this application are the annual seroconversion rates from 1978 to 1983, not otherwise obtainable in this study population.

Entities:  

Mesh:

Year:  1991        PMID: 1805323     DOI: 10.1002/sim.4780101212

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  10 in total

1.  Mortality in Children with Human Immunodeficiency Virus Initiating Treatment: A Six-Cohort Study in Latin America.

Authors:  Marco T Luque; Cathy A Jenkins; Bryan E Shepherd; Denis Padgett; Vanessa Rouzier; Regina Célia M Succi; Daisy M Machado; Catherine C McGowan; Sten H Vermund; Jorge A Pinto
Journal:  J Pediatr       Date:  2017-01-09       Impact factor: 4.406

2.  Using Registry Data to Construct a Comparison Group for Programmatic Effectiveness Evaluation: The New York City HIV Care Coordination Program.

Authors:  McKaylee M Robertson; Levi Waldron; Rebekkah S Robbins; Stephanie Chamberlin; Kate Penrose; Bruce Levin; Sarah Kulkarni; Sarah L Braunstein; Mary K Irvine; Denis Nash
Journal:  Am J Epidemiol       Date:  2018-09-01       Impact factor: 4.897

Review 3.  Observational research on NCDs in HIV-positive populations: conceptual and methodological considerations.

Authors:  Maya Petersen; Constantin T Yiannoutsos; Amy Justice; Matthias Egger
Journal:  J Acquir Immune Defic Syndr       Date:  2014-09-01       Impact factor: 3.731

4.  Correlates of syphilis seroreactivity among pregnant women: the HIVNET 024 Trial in Malawi, Tanzania, and Zambia.

Authors:  Dara Potter; Robert L Goldenberg; Jennifer S Read; Jing Wang; Irving F Hoffman; Elmar Saathoff; George Kafulafula; Said Aboud; Francis E A Martinson; Maysoon Dahab; Sten H Vermund
Journal:  Sex Transm Dis       Date:  2006-10       Impact factor: 2.830

5.  CC chemokine receptor 5 genotype and susceptibility to transmission of human immunodeficiency virus type 1 in women.

Authors:  Sean Philpott; Barbara Weiser; Patrick Tarwater; Sten H Vermund; Cynthia A Kleeberger; Stephen J Gange; Kathryn Anastos; Mardge Cohen; Ruth M Greenblatt; Andrea Kovacs; Howard Minkoff; Mary A Young; Paolo Miotti; Michelle Dupuis; Chih-Hsiung Chen; Harold Burger
Journal:  J Infect Dis       Date:  2003-01-29       Impact factor: 5.226

6.  Symptomatic HIV-positive persons in rural Mozambique who first consult a traditional healer have delays in HIV testing: a cross-sectional study.

Authors:  Carolyn M Audet; Meridith Blevins; Caitlin Rosenberg; Sarah Farnsworth; José Salato; Jorge Fernandez; Sten H Vermund
Journal:  J Acquir Immune Defic Syndr       Date:  2014-08-01       Impact factor: 3.731

7.  Predictors of adherence to antiretroviral therapy in rural Zambia.

Authors:  James G Carlucci; Aniset Kamanga; Robb Sheneberger; Bryan E Shepherd; Cathy A Jenkins; John Spurrier; Sten H Vermund
Journal:  J Acquir Immune Defic Syndr       Date:  2008-04-15       Impact factor: 3.731

8.  An empirical approach to defining loss to follow-up among patients enrolled in antiretroviral treatment programs.

Authors:  Benjamin H Chi; Ronald A Cantrell; Albert Mwango; Andrew O Westfall; Wilbroad Mutale; Mohammed Limbada; Lloyd B Mulenga; Sten H Vermund; Jeffrey S A Stringer
Journal:  Am J Epidemiol       Date:  2010-03-10       Impact factor: 4.897

9.  Incidence of WHO stage 3 and 4 conditions following initiation of anti-retroviral therapy in resource limited settings.

Authors:  Andrea J Curtis; Catherine S Marshall; Tim Spelman; Jane Greig; Julian H Elliot; Leslie Shanks; Philipp Du Cros; Esther C Casas; Marcio Silveria Da Fonseca; Daniel P O'Brien
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

10.  Short-term effectiveness of HIV care coordination among persons with recent HIV diagnosis or history of poor HIV outcomes.

Authors:  Denis Nash; McKaylee M Robertson; Kate Penrose; Stephanie Chamberlin; Rebekkah S Robbins; Sarah L Braunstein; Julie E Myers; Bisrat Abraham; Sarah Kulkarni; Levi Waldron; Bruce Levin; Mary K Irvine
Journal:  PLoS One       Date:  2018-09-24       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.